Fig. 1.

SFX inhibits the secretion of sEV from breast cancer cells quantitatively and qualitatively. a Screening flow chart of primary and secondary screenings with some exclusion criteria to identify an inhibitor of sEV secretion, sulfisoxazole. b The number of secreted sEV with the indicated concentrations of SFX. n = 3. c Left, electron microscopy image. Scale bar, 100 nm. Right, Quantification of the number of secreted sEV. Randomized fields were captured and counted. n = 30. d Measurement of the microvesicle concentration by nanoparticle tracking analysis (NTA). n = 3. e Measurement of soluble cytokines secreted from MDA-MB231 cells. n = 3. f qRT-PCR analysis of the indicated miRNAs in MDA-MB231 cells after treatment of 100 μM SFX. n = 3. The GEO accession number of miRNA microarray set is GSE124320. g Immunoblot of various proteins in MDA-MB231 cell-derived sEV. Equal amounts of sEV protein (10 μg) were loaded per lane. n = 3. Experiments were performed with 95% confluent cells. Significance was determined using an unpaired two-tailed Student’s t- test. ***p < 0.001, **p < 0.005, and *p < 0.05. Error bar, SD. Source data (b–g) are provided as a Source Data file